ORAL BIOLOGICS MARKET ANALYSIS

Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023
Code : CMI989
Pages :197
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Oral Biologics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global oral biologics market over the forecast period. North America is estimated to hold 40.0% of the market share in 2023. The global oral biologics market is expected to witness significant growth in the coming years, driven by the high prevalence of Irritable Bowel Syndrome, favorable health reimbursement, and increased awareness. The increasing prevalence of irritable bowel syndrome (IBS) is contributing to the growth of the surgical equipment market in the North America region. For instance, according to the American College of Gastroenterology, 2020, about 10% to 15% of people in the U.S. suffer from IBS symptoms annually.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa